

11-09-2000

T-676 P.006/016 F-645

PATENTS ONLY

PATENTS ONLY

N/9/00

TO THE HON  
Please recd



101505519

REMARKS  
hereof

ON AN EXPEDITED BASIS

1. Name of conveying party(ies)  
Protein Engineering Corporation

2. Name and Address of receiving party(ies)  
Name: Dyax Corp  
Address: One Kendall Square, Building 600, Fifth Floor,  
Cambridge, Massachusetts 02139

Additional name(s) & address(es) attached?  Yes  No

Additional name(s) of conveying party(ies) attached?  Yes  No

3. Nature of conveyance:  
 Assignment  Change of Name  
 Security Agreement  Merger

Other: Document previously recorded at reel 8535 frame 0123  
contained error 5,223,345. Document re-recorded to correct error  
on stated reel, should be 5,223,409.

Execution Date: January 21, 1997 (original assignment)

4. Application number(s) or patent number(s)

A. Patent Application No(s).

B. Patent No(s).

5,223,409

Additional numbers attached?  Yes  No

5. Name and address of party to whom correspondence  
concerning document should be mailed:

BROWDY AND NEIMARK, P.L.L.C.,  
624 Ninth Street, N.W.  
Suite 300  
Washington, D.C. 20001-5303  
(202) 628-5197

6. Number of applications and patents involved:  
(1)

7. Amount of fee enclosed or authorized to be charged:  
\$160.00 (expedited service—call and hold for pickup)

8. PTO Form-2038 in the amount of \$160.00 is attached.

11/09/2000 DNGUYEN 00000043 5223409

Do Not Use This Space

01 FC:581  
02 FC:584

40.00 0P  
120.00 0P

9. Statement and Signature.

To the best of my knowledge and belief, the foregoing information is true and correct and any attached copy is a true copy of the original document.

Iver Cooper (Reg. No. 28,005)

Name of Person Signing

Signature

10/10/00

Date

IPC:

Total number of pages including cover sheet [01]

TO THE HO  
Please record

2027373528

T-676 P.007/016 F-645

100434158

102542206

~~JAN 9 1997~~

RECEIPT ACCOUNTING DIV.

1. Name of conveying party(ies):  
PROTEIN ENGINEERING CORPORATION

2. Name and Address of receiving party(ies):  
Name: DYAX CORP.  
Address: One Kendall Square  
Building 600, Fifth Floor,  
Cambridge, MA 02139

Additional name(s) of conveying party(ies) attached? [ ] Yes [X] No

Additional name(s) & address(es) attached? [ ] Yes [X] No

3. Nature of conveyance:

- Assignment                      [ ] Change of Name                      [ ] Other \_\_\_\_\_
- Security Agreement                      [ ] Merger

Execution Date: January 21, 1997

4. Application number(s) or patent number(s). If this document is being filed together with a new application, the execution date of the application is: \_\_\_\_\_ Date

A. Patent Application No.(s)

B. Patent No.(s)

08/415,922  
08/358,160  
08/208,264  
08/676,125  
08/676,124

5,096,815  
5,198,346  
5,223,346  
5,403,484  
5,571,698

Additional numbers attached? [ ] Yes [X] No

5. Name and address of party to whom correspondence concerning document should be mailed:

BROWDY AND NEIMARK, P.L.L.C.  
419 Seventh Street, N.W.  
Suite 300  
Washington D.C. 20004

6. Number of applications and patents involved:  
( 10 )

7. Amount of fee enclosed or authorized to be charged: \$400.00 \*

8. Check no. 16386 in the amount of \$400.00 is attached.

Do Not Use This Space

9. Statement and Signature.

To the best of my knowledge and belief, the foregoing information is true and correct and any attached copy is a true copy of the original document.

Iver P. Cooper (Reg. No. 28,005)

Name of Person Signing

Signature

1/21/97

Date

IPC:wrb \*Please charge any deficiency to Deposit Account 02-4035

Total number of pages comprising cover sheet (0)

MWD 06-04-97

WORLDWIDE ASSIGNMENT AND DECLARATION OF ACCEPTANCE

Effective December 31, 1996, PROTEIN ENGINEERING CORPORATION, of One Kendall Square, Building 600, Fifth Floor, Cambridge, MA 02139, a wholly owned subsidiary of DYAX CORP., hereby assigns to DYAX, CORP., of One Kendall Square, Building 600, Fifth Floor, Cambridge, MA 02139, all right, title and interest in the applications and patents identified below, including all rights of priority asserted therein, and in any continuations, divisions, continuations-in-part or extensions thereof, and DYAX CORP. hereby declares its acceptance of said assignment.

USSN 07/293,980, U.S. Patent No. 5,096,815, filed January 6, 1989, GENERATION AND SELECTION OF NOVEL DNA-BINDING PROTEINS... (LADNER3-USA);

USSN 07/558,011, U.S. Patent No. 5,198,346, filed July 26, 1990, GENERATION AND SELECTION OF NOVEL DNA-BINDING PROTEINS... (LADNER3.1-USA);

USSN 07/664,989, U.S. Patent No. 5,223,409, filed March 1, 1991, DIRECTED EVOLUTION OF NOVEL BINDING PROTEINS (LADNER7-USA);

USSN 08/009,319, U.S. Patent No. 5,403,484, filed January 26, 1993, VIRUSES EXPRESSING CHIMERIC BINDING PROTEINS (LADNER7D-USA);

USSN 08/057,667, U.S. Patent No. 5,571,698, filed June 18, 1993, DIRECTED EVOLUTION OF NOVEL BINDING PROTEINS (LADNER7E-USA);

USSN 08/415,922, filed April 3, 1995, VIRUSES EXPRESSING CHIMERIC BINDING PROTEINS (LADNER7F-USA);

USSN 08/358,160, filed December 16, 1994, ENGINEERED HUMAN-DERIVED KUNITZ DOMAINS THAT INHIBIT HUMAN NEUTROPHIL ELASTASE (LEY1-USA);

USSN 08/208,264, filed March 10, 1994, KALLIKREIN-BINDING "KUNITZ DOMAIN" PROTEINS (MARKLAND1A-USA);

USSN 08/676,125, filed July 11, 1996, KALLIKREIN-INHIBITING "KUNITZ DOMAIN" PROTEINS AND ANALOGUES (MARKLAND1B-USA);

USSN 08/676,124, filed July 11, 1996, INHIBITORS OF HUMAN PLASMIN DERIVED FROM THE KUNITZ DOMAINS (MARKLAND13-USA);

Canadian Appl. No. 610,176, filed September 1, 1989, GENERATION AND SELECTION OF NOVEL BINDING PROTEINS (LADNER1-CANA);

Canadian Appl. No. 2,103,300, filed February 27, 1992, PROCESS FOR THE DEVELOPMENT OF BINDING MINI-PROTEINS... (LADNER7A-CANA);

Canadian Appl. No. 2,105,304, filed February 28, 1992, INHIBITORS OF HUMAN NEUTROPHIL ELASTASE AND HUMAN CATHEPSIN (LADNER7C-CANA);

Canadian Appl. No. 2,180,950, filed January 11, 1995, KALLIKREIN-INHIBITING "KUNITZ DOMAIN" PROTEINS AND ANALOGUES (MARKLAND1B-CANA);

Canadian Appl. No. 2,180,954, filed January 11, 1995, INHIBITORS OF HUMAN PLASMIN DERIVED FROM THE KUNITZ DOMAINS (MARKLAND3B-CANA);

European Appl. No. EP89/910702.3, filed September 1, 1989, GENERATION AND SELECTION OF RECOMBINANT VARIED BINDING PROTEINS (LADNER1-EPC);

European Appl. No. EP96/112867.5, filed September 1, 1989, GENERATION AND SELECTION OF RECOMBINANT VARIED BINDING PROTEINS (LADNER1A-EPC);

European Appl. No. EP90/902463.1, filed January 5, 1990, GENERATION AND SELECTION OF NOVEL DNA-BINDING PROTEINS... (LADNER3-EPC);

European Appl. No. EP92/908057.0, filed February 27, 1992, PROCESS FOR THE DEVELOPMENT OF BINDING MINI-PROTEINS... (LADNER7A-EPC);

European Appl. No. EP92/908799.7, filed February 28, 1992, IMPROVED EPITOPE DISPLAYING PHAGE... (LADNER7B-EPC);

European Appl. No. EP92/908481.2, filed February 28, 1992, INHIBITORS OF HUMAN NEUTROPHIL ELASTASE AND HUMAN CATHEPSIN (LADNER7C-EPC);

European Appl. No. EP95/909223.0, filed January 11, 1995, KALLIKREIN-INHIBITING "KUNITZ DOMAIN" PROTEINS AND

ANALOGUES (MARKLAND1B-EPC);

European Appl. No. EP95/908460.9, filed January 11, 1995,  
INHIBITORS OF HUMAN PLASMIN DERIVED FROM THE KUNITZ  
DOMAINS (MARKLAND3B-EPC);

Ireland Appl. No. IR89/2834, filed September 4, 1989,  
GENERATION AND SELECTION OF NOVEL BINDING PROTEINS  
(LADNER1-IREL);

Ireland Appl. No. 59\90, filed January 8, 1990,  
GENERATION AND SELECTION OF NOVEL DNA-BINDING PROTEINS  
AND... (LADNER3-IREL);

Israeli Appl. No. 091,501, filed September 1, 1989,  
GENERATION AND SELECTION OF NOVEL BINDING PROTEINS  
(LADNER1-ISRA);

Japanese Appl. No. 1-510087, filed September 1, 1989,  
GENERATION AND SELECTION OF NOVEL BINDING PROTEINS  
(LADNER1-JAPA);

Japanese Appl. No. JP90/502436, filed January 5, 1990,  
GENERATION AND SELECTION OF NOVEL DNA-BINDING PROTEINS  
AND... (LADNER3-JAPA);

Japanese Appl. No. 4-507558, filed February 27, 1992,  
PROCESS FOR THE DEVELOPMENT OF BINDING MINI-PROTEINS  
(LADNER7A-JAPA);

Japanese Appl. No. 5-508216, filed February 28, 1992,  
IMPROVED EPITOPE DISPLAYING PHAGE (LADNER7B-JAPA);

Japanese Appl. No. 4-508204, filed February 28, 1992,  
INHIBITORS OF HUMAN NEUTROPHIL ELASTASE AND HUMAN  
CATHEPSIN G (LADNER7C-JAPA);

Japanese Appl. No. 7-518726, filed January 11, 1995,  
KALLIKREIN-INHIBITING "KUNITZ DOMAINS" PROTEINS AND  
ANALOGUES (MARKLAND1B-JAPA);

Japanese Patent Application No. 7-518667, filed January  
11, 1995, INHIBITORS OF HUMAN PLASMIN DERIVED FROM THE  
KUNITZ DOMAINS (MARKLAND3B-JAPA);

PCT/US95/16349, filed December 15, 1995, ENGINEERED  
HUMAN-DERIVED KUNITZ DOMAINS THAT INHIBIT HUMAN  
NEUTROPHIL ELASTASE (LEY1A-PCT).

